Somatropin Effect on Linear Growth and Final Height in Subjects With Noonan Syndrome

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

24 participants

Study Classification

INTERVENTIONAL

Study Start Date

1990-06-30

Study Completion Date

2005-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This trial is conducted in Europe. The aim of this trial is to evaluate the effect of somatropin (Norditropin®) on final height in children with Noonan syndrome having being treated for up to 10 years with somatropin (Norditropin®) for the attainment of an optimal final height in the original trial S/GHD/004/NOO.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Use of Somatropin in Turner Syndrome

NCT01518036

Genetic Disorder Turner Syndrome

COMPLETED PHASE3

Genetic Testing of Noonan Subjects Previously Treated With Norditropin®. An Extension to Trial GHNOO-1658

NCT01529944

Genetic Disorder Noonan Syndrome

COMPLETED PHASE3

Somatropin (Norditropin) in Insulin-like Growth Factor (IGF) Deficient Children

NCT00102817

Growth Hormone Disorder Pituitary Dwarfism

COMPLETED PHASE3

Investigating the Long-term Efficacy and Safety of Two Doses of NN-220 (Somatropin) in Short Stature Due to Noonan Syndrome

NCT01927861

Genetic Disorder Noonan Syndrome

COMPLETED PHASE3

Safety and Efficacy of Somatropin in Children With Growth Hormone Deficiency

NCT01502124

Growth Hormone Disorder Growth Hormone Deficiency in Children

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Genetic Disorder Noonan Syndrome

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Low dose 33 mcg/kg/day

Group Type EXPERIMENTAL

somatropin

Intervention Type DRUG

Retrospective data collection based on data obtained from a prospective, open-label, randomised, parallel-group trial (S/GHD/004/NOO) combined with a present follow-up visit

High dose 66 mcg/kg/day

Group Type EXPERIMENTAL

somatropin

Intervention Type DRUG

Retrospective data collection based on data obtained from a prospective, open-label, randomised, parallel-group trial (S/GHD/004/NOO) combined with a present follow-up visit

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

somatropin

Retrospective data collection based on data obtained from a prospective, open-label, randomised, parallel-group trial (S/GHD/004/NOO) combined with a present follow-up visit

Intervention Type DRUG

somatropin

Retrospective data collection based on data obtained from a prospective, open-label, randomised, parallel-group trial (S/GHD/004/NOO) combined with a present follow-up visit

Intervention Type DRUG